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Monoclonal antibodies (mAbs) are widely used due to their exquisite specificity and once were hailed 
as the solution to cancer. However, when mouse mAbs are administered in humans, anti-antibody 
response (AAR) is frequently observed. Using humanized mAbs which are commonly developed by 
CDR-grafting method, the AAR is negligible, but loss of binding has also been consistently reported. 
Therefore, in an effort to produce humanized anti-C2 mAbs that retain binding properties but produce 
minimal AAR, humanized mAb has been developed by logical approach using IgBLAST. The purity and 
functionality of humanized mAb was confirmed by Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and cell-based assays, respectively. Although the humanized mAb 
developed using logical approach had reduced AAR compared to mouse anti-C2 mAb in Macaca 
fascicularis, however the AAR was higher, compared to humanized mAb developed using 
deimmunization method. Hence, for the development of functional humanized mAbs with negligible 
AAR, it is recommended that amphipathic mouse residues, excluding those located in the CDR or 
Vernier zone, be chosen for humanization. However, humanization of every amphipathic mouse 
residues is unnecessary because with minimal judicious amino acid substitutions, an AAR response 
can be minimized without jeopardizing the immunoreactivity, hence making it ideal for use in human 
therapeutics. 
 
Key words: Antibody humanization, cell-based assay, immunogenicity, Macaca fascicularis, site-directed 
overlapping-PCR mutagenesis. 
 
 
INTRODUCTION 
 
The use of monoclonal antibodies (mAbs) generated from 
hybridoma technology for diagnosis and treatment of 
human cancers has been the subject of intense research 
for many years (Zafir-Lavie et al., 2007). Unfortunately, 
since mouse splenocytes are used, the resulting mouse 
mAbs   are   likely  to  induce  an  anti-antibody  response  
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(AAR), known as human anti-mouse antibody (HAMA) 
response when administered in humans (Hwang and 
Foote, 2005). Although the use of chimeric mAbs may 
reduce the AAR, because chimeric mAbs still contain 
approximately one third of antibody of mouse origin, it 
could still induce a significant AAR, known as human 
anti-chimeric antibody response (HACA). On the other 
hand, humanized mAbs which are commonly developed 
by complementary determining regions (CDR)-grafting 
method may have negligible AAR, but are often non-
functional due to the loss of antigen-binding function. This 
 
 
 
 
is because some non-CDR mouse residues in the 
framework are still required for the effective binding of 
humanized mAbs and injudicious substitution of critical 
residues that maintain the CDR conformation required for 
specific binding to antigen may cause loss of binding 
ability (Mateo et al., 2000). Consequently, tedious and 
laborious back mutations are required to restore their 
functionality. Therefore, in the process of humanization, it 
would be desirable to substitute mouse amino acid 
residues in the variable region as judiciously as possible. 
A high degree of homology in the mouse and human 
framework will ensure that the CDR will have the greatest 
chance of retaining the binding properties. However, 
there will still be a certain degree of amino acid mismatch 
in these frameworks between human and mouse 
antibodies, which may give rise to AAR. Thus careful 
consideration of strategic substitution of these 
mismatched residues is needed for the humanized mAb 
to maintain binding affinity and at the same time induces 
minimize AAR when being administered in human. 
In this communication, we describe the generation of 
humanized mAb against the C2 antigen, which is 
specifically expressed in colorectal carcinoma cells, from 
mouse mAbs. Here, only limited residues in the mouse 
framework region having the highest homology to the 
corresponding human framework region were considered 
for humanization. Humanized anti-C2 mAb (H2C2 mAb) 
was developed using logical approach method and was 
compared to our previous version of humanized anti-C2 
mAb (H1C2 mAb), developed using deimmunization 
method (Roque-Navarro et al., 2003, Dharshanan et al., 
2011a). The purity and functionality of both humanized 
mAbs were characterized in vitro using SDS-PAGE and 
cell-based assays, respectively, while the immunogenicity 
was characterized in vivo using Macaca fascicularis 
monkeys.   
 
 
MATERIALS AND METHODS 
 
Development of humanized mAbs  
 
Construction of expression vectors with variable region of 
mouse antibody 
 
The mouse VH and VL were constructed using a method described 
(Roque-Navarro et al., 2003). Briefly, total RNA was extracted from 
mouse hybridoma secreting anti-C2 antibody and was used to 
synthesize the cDNA of VH and VL. Both cDNAs were amplified 
using PCR and were ligated to pCR2.1-TOPO cloning vectors using 
TOPO-TA cloning kit (cat. no.: K4500-01, Life Technologies, USA). 
The resulting vectors were named mouse-pVH for VH and mouse-
pVL for VL. 
 
 
Humanization of mouse anti-C2 mAb using logical approach 
method 
 
To determine the amino acids of VH and VL of mouse anti-C2 that 
differ with its homologous human amino acids, 100 most 
homologous human sequences for each VH and VL were obtained  
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from the IgBLAST software (http://www.ncbi.nlm.nih.gov/igblast/). 
From the mouse-human amino acids comparison, the mouse 
framework with the highest homology to its corresponding human 
framework was determined. The mismatched mouse-human 
residues (if present) were considered candidates for substitution 
only if the corresponding human amino acid was present in 90% of 
the total human variable regions analyzed. Then the mismatched 
mouse-human residues in that framework were substituted with the 
residue occurring with the highest frequency in corresponding 
human framework. 
 
 
Construction of expression vectors with variable region of 
human antibody 
 
The substitution was executed by overlapping-PCR mutagenesis 
using primers shown in Table 1. Primers prefixed H and L was used 
for VH and VL, respectively. For both VH and VL, primers HF0-1 
and LF0-2 were used as forward primers, while primers HR0-1 and 
LR0-2 were used as reverse primers. Primers numbered 1 and 2 
were mutagenic primers containing nucleotide substitution (letters 
underlined and bolded) in its DNA sequence to introduce the 
specific amino acid conversion at the desired residues. All primers 
were synthesized by First BASE Laboratories (Selangor, Malaysia).  
 
 
Humanization of residue 10 of mouse VH and residue 68 of 
mouse VL: Each of the site-specific mutagenesis was done by 
three sets of PCRs outlined below: 
  
(i) PCR-1; the mixture contained 48.0 l of master-mix components 
and 1.0 l each of primers HF0/LF0 and HR1/LF1.  
(ii) PCR-2 contained the exact components as PCR-1 except that 
primers HF1/LF1 and HR0/LF0 were used instead. The master-mix 
was made up of 10.0 l of reaction buffer (10×), 2.0 l of dNTPs (10 
mM), 2.0 l of recombinant Taq DNA polymerase, 3.0 l of MgCl, 
73.0 l of sterile water and 6.0 l of mouse-pVH/mouse-pVL 
vectors. The two PCR products were then purified before being 
merged using overlapping-PCR (PCR-3). 
(iii) PCR-3 (overlapping-PCR); the mixture was similar to the 
master-mix of PCR-1 and 2 with the following exception, 76.0 l of 
sterile water, 1.0 l of recombinant Taq DNA polymerase, 1.0 l of 
each primer HF0/LF0 and HR0/LR0 were used and the mouse-
pVH/mouse-pVL vectors were substituted with 3.0 l of each 
purified PCR-1 and PCR-2 products for a final volume of 100 l. 
Vectors with the desired sequences were determined and named 
humanized-pVH1 (VH) and humanized-pVL1 (VL).  
 
 
Humanization of residue 81 of mouse VL: The mutations of these 
residues were performed as described earlier with the following 
differences: 
 
(i) Humanized-pVL1 (in both PCR-1 and PCR-2) was used instead 
of mouse-pVL vectors. 
(ii) Primers LF1 and LR1 were replaced with LF2 and LR2, 
respectively. Vectors with the desired sequences were determined 
and named humanized-pVL2. 
 
All PCR reactions were executed using the following steps: (1) 
94°C for 3 min; (2) 94°C for 40 s; (3) 55°C for 30 s; (4) 72°C for 90 
s; (5) repeat step 2 to 4 for 30 cycles; (6) 72°C for 10 min, and 
finally cooling to 4°C. The products of PCR-3 were purified, ligated  
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Table 1. List of primers and their DNA sequences. Primers with underlined and bold nucleotide 
are mutagenesis primers designed to introduce mutations at specific mouse residues to its 
homologous human residues 
 
Primer name Primer sequence 
HF0 5'-GGGGATATCCACCATGGCTGTCTTGGGGCTGCTCTTCT-3’ 
HR0 5'-GGGGCTAGCTGCAGAGACAGTGACCAGAGT-3’ 
HF1 5'-GAGTCAGGACCTGGCCTGGTGAAACCT-3’ 
HR1 5'-AGGTTTCACCAGGCCAGGTCCTGACTC-3’ 
LF0 5'-GGGGATATCCACCATGAGGTCCCCTGCTCAGCTC-3’ 
LR0 5'-AGCGTCGACTTACGTTTTATTTCCAGCTTGGTCCC-3’ 
LF1 5'-CCTGACAGATTCAGTGGCAGTGGATCA-3’ 
LR1 5'-TGATCCACTGCCACTGAATCTGTCAGG-3’ 
LF2 5'-GATTTCGCACTGAAAATCAGCAGAGTG-3’ 
LR2 5'-CACTCTGCTGATTTTCAGTGCGAAATC-3’ 
 
 
 
to a cloning vector and transformed into competent bacterial cells. 
Plasmids were isolated from 24 bacterial clones and were sent for 
DNA sequence determination at First BASE Laboratories. The 
plasmids with the desired humanized VH and VL DNA sequences 
were then sub-cloned into expression vectors pAH4602, which 
contains the human IgG1 constant regions (for VH), and pAG4622, 
which contains the human kappa constant region (for VL) (Morrison 
et al., 1984). The recombinant vectors were named humanized-
pAH4602 for humanized VH and humanized-pAG4622 for 
humanized VL. 
 
 
Expression, production and purification of humanized 
antibodies 
 
For the expression of H2C2 mAb, plasmids humanized-pAH4602 
and humanized-pAG4622 were used. Both plasmids were co-
transfected into NS0 cells and the high producer clones were 
selected using the ClonePix FL system. The best clone in terms of 
stability and productivity for each mAb, namely H2C2 (logical 
approach method), H1C2 (developed previously using 
deimmunization method), chimeric anti-C2 (QC2) and mouse anti-
C2 (MC2) mAb was chosen and adapted to serum-free growth 
media (Dharshanan et al., 2011b). For small-scale production of 
mAbs, triple flasks were used and the secreted mAbs were purified 
by Protein A affinity chromatography using Äkta Prime plus. 
 
 
Characterization of mAbs 
 
SDS-PAGE  
 
All purified mAbs were analyzed by SDS-PAGE under reducing and 
non-reducing conditions according to Laemmli (1970). The SDS-
PAGE gel consisted of a 10% (v/v) separating gel topped by a 5% 
(v/v) stacking gel. Full range Rainbow marker (GE Healthcare, 
USA) was used as a reference for the estimation of the molecular 
weight of the protein bands. 
 
 
In vitro binding studies 
 
Immunofluorescence cell-based assay: Since it is critical to 
evaluate the functionality of hum-C2 mAbs after humanization, a 
cell-based ELISA was performed using a method described with 
modifications (Hong et al., 2004). The SW1116 colorectal cancer 
cell line (cat. no.: CCL-23, ATCC, USA) which expresses the C2 
antigen on its cell surface was used. The cell line was grown at 
37°C using Leibovitz’s L-15 medium (Sigma-Aldrich, USA) 
supplemented with 10% fetal bovine serum (Biochrom, Germany). 
For the preparation of fixed cell-based ELISA, 96 well plates were 
cultured with 200 l of 104 SW1116 cells/well and incubated at 
37°C for 72 h. Plates were then washed three times with 200 l of 
washing buffer (sterile water containing 0.09% sodium chloride and 
0.05% tween-20) to remove previous media. The cells were then 
fixed using 200 l of fixation solution and incubated at room 
temperature for 5 min. The fixation solution is a mixture of acetone 
and methanol at equal volumes. Wells were washed before they 
were blocked by the addition of 200 l of blocking buffer (pH 7.4 
phosphate buffer (1 M) containing 3% bovine serum albumin (BSA) 
and 0.1% tween-20) into each well and incubated at 37°C for 90 
min. Wells were then washed 3 times with washing buffer. Next, 
100 l of 200 ng/ml purified H1C2 and H2C2 mAbs were added in 
triplicate to designated wells. For positive controls, wells were 
reacted with 100 l of 200 ng/ml of mouse (MC2) and chimeric 
(QC2) anti-C2 mAbs. For negative controls, 100 l of 200 ng/ml 
immunopure human IgG (cat. no.: 31154, Thermo Fisher Scientific, 
USA) and immunopure mouse IgG (cat. no.: 31202, Thermo Fisher 
Scientific, USA) were added. All samples were diluted using pH 7.4 
phosphate buffer (1 M) prior to use. Wells were incubated at 37°C 
for 90 min and washed thrice with washing buffer, and binding of 
primary antibody was assessed using appropriate FITC-conjugated 
secondary antibodies. Anti-human secondary antibody was added 
to wells reacted with chimeric, humanized and human antibodies 
while anti-mouse secondary antibody was added to wells reacted 
with mouse antibodies. The secondary antibodies used were diluted 
to a ratio of 1:64 in phosphate buffer before use. Then, 100 l of 
diluted secondary antibodies conjugated to FITC: anti-human 
detection agent-FITC (cat. no.: K8200, Molecular Devices, USA) or 
anti-mouse detection agent-FITC (cat. no.: K8220, Molecular 
Devices, USA) were added. The mixtures were incubated at 37°C 
for 60 min and unbound secondary antibodies were removed by 
washing with washing buffer before 50 l of sterile water were 
added. The cell binding was visualized under a fluorescence 
microscope (Nikon, USA). 
 
Competitive cell-based ELISA: To evaluate the affinity of the 
humanized mAb to C2 antigen, a competitive cell-based ELISA was 
performed. The fixation of SW1116 cells, blocking  and  washing  of 
 
 
 
 
the plates were similarly performed as described in immunofluo-
rescence cell-based assay. Next, 50 l of 0.1, 1.0 and 10.0 g/ml of 
purified H1C2, H2C2 and QC2 mAbs were each mixed with 50 l of 
1.0 g/ml of purified MC2 mAb. The mixtures were then added in 
triplicate to designated wells. For negative control, 
immunopureHuman IgG was used. The plates were incubated at 
37°C for 90 min. Wells were washed 3 times with washing buffer 
and 100 l of diluted secondary antibody: anti-mouse IgG 
conjugated to peroxidase enzyme (cat. no. A3673, Sigma-Aldrich) 
were added to each well. The secondary antibody used is specific 
to the γ-chain of mouse mAbs and was diluted to a ratio of 1:2500 
in phosphate buffer before use. The mixtures were again incubated 
at 37°C for 60 min. Unbound secondary antibodies were removed 
by washing, and 100 l ABTS substrate solution (cat. no. 
11112422001 and 11112597001, Roche) were added. The mixture 
was incubated at room temperature in the absence of light for 30 
min. Finally, the enzyme-substrate reaction was stopped by adding 
50 l of 0.5 M of sulfuric acid and absorbance was measured at 405 
nm using a Synergy HT multi-mode microplate reader (BioTek, 
Winooski, Vermont, USA). 
 
 
In vivo immunogenicity studies 
 
To predict the immunogenicity of H1C2 and H2C2 mAbs in humans, 
non-human primates, macaque monkeys (M. fascicularis) were 
used. The use of monkeys for this study was approved by the 
Animal Care and Use Committee (ACUC), Laboratory Animal 
Science Centre, Faculty of Medicine, University of Malaya and 
granted ACUC ethics number: FIS/14/07/2010/SD (R). All 
procedures were performed on anesthetized M. fascicularis under 
the supervision of a veterinarian.  
 
Immunization and blood collection of M. fascicularis: Five 
captive-born monkeys between 2 to 4 years old were obtained from 
Laboratory Animal Science Centre, University of Malaya. Each 
monkey was randomly chosen to be immunized with either with 
H1C2, H2C2, QC2, MC2 mAbs or placebo. For the first 
immunization, 0.2 mg mAb emulsified in 1 ml of complete Freund’s 
adjuvant (CFA) (Sigma-Aldrich, USA) were injected into each 
monkey. For subsequent booster immunizations, CFA was replaced 
with incomplete Freund’s adjuvant (IFA) (Sigma-Aldrich, USA). 
Placebo consisted of adjuvants emulsified in the absence of mAb. 
Antibodies or placebo were injected intradermically at 5 different 
spots with approximately 0.2 ml per spot on day 0, 14, 28 and 42. 
Prior to each immunization, monkeys were anaesthetized with 
Zoletil (Virbac, USA) at a dose of 8 mg/kg through intramuscular 
injection. Then, the mass of each monkey was measured, and 
blood was collected on day 0, 14, 28, 42 and 56 from the cephalic 
vein using needle and syringe. Blood was immediately transferred 
to EDTA-treated tubes, inverted several times and centrifuged at 
2000 rpm for 5 min at 4°C. The plasma samples were then 
aliquoted into small volumes into PCR tubes and stored at -20°C. 
 
Measurement of monkeys’ anti-antibody response: The AAR 
responses were determined by the measurement of blood IgM and 
IgG levels employing ELISA methods. Briefly, purified MC2 mAb (1 
g/ml) or purified QC2 mAb (1 g/ml) were used as capture 
antibodies, anti-monkey IgM (cat. no.: 617-103-007, Rockland 
Immunochemicals, USA) and anti-monkey IgG (cat. no.: A2054, 
Sigma-Aldrich, USA) were used as the secondary antibodies to 
detect IgM and IgG levels, respectively. Both secondary antibodies 
are conjugated to peroxidase and were diluted to a ratio of 1:2500 
in phosphate buffer before use. Monkey plasma samples were 
diluted to a ratio of 1:2500 and 1:5000 in phosphate buffer. 
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RESULTS  
 
Development of humanized monoclonal antibodies 
 
In the development of humanized mAb from mouse mAb, 
our principle was to judiciously and minimally substitute 
the amino acids on the variable region of mouse mAb in 
order to maximize probability of retention of reactivity and 
to minimize the incidence of AAR. In order to develop the 
humanized anti-C2 mAb, the VH and VL of mouse mAb 
were first aligned and compared to that of human in order 
to determine the frameworks that had the highest degree 
of homology. From the comparison, it was found that 
frameworks 1 and 3 for VH and VL had the highest 
degree of homology (75.9 and 87.8%, respectively) 
(Table 2a) and thus were chosen to be the targets for 
humanization. Due to the high degree of homology 
between mouse and human residues, it was felt that 
humanization on this framework would be least likely to 
affect the functionality of the humanized antibodies.  
Using logical approach method to further minimize 
AAR, within each framework, the mismatched residues 
was humanized only if the corresponding human amino 
acid was present in at least 90% of all the homologous 
human variable regions analyzed. In framework 1 of VH, 
four mismatched mouse-human residues were present 
(Table 2b), but only aspartic acid at residue 10 was 
targeted for substitution to the corresponding human 
amino acid, glycine, which is the most abundant (91.2%) 
on the human framework. Coincidently, this residue was 
also humanized to glycine in the deimmunization method 
of H1C2 mAb. The other three mouse residues (16-Q, 
17-S and 25-T) were not humanized because the 
corresponding human amino acids were present at less 
than 90% frequency (Table 2b). Similarly, three 
mismatched mouse-human residues were found in the 
framework 3 of VL (Figure 2c) but only two of the 
mismatched residues, 68 (threonine) and 81 (arginine) in 
mouse were substituted with the corresponding most 
abundant amino acid in the human framework, that is 
serine (100%) and serine (90.3%), respectively. 
Coincidently, residue 68-T was also humanized to serine 
in the deimmunization method of H1C2 mAb. Residue 
88-L was not humanized because corresponding human 
amino acids were present with less than 90% frequency. 
It must be noted that other mismatched residues which 
are located in the CDR and Vernier zone, and therefore 
contribute to the antigen binding function of mAbs are not 
substituted (Roque-Navarro et al., 2003). The use of site-
directed overlapping-PCR mutagenesis (Figure 1) has 
made it possible to develop H2C2 mAb with the amino 
acid substitutions at the desired residues. However, a 
large number DNA samples had to be sequenced 
because out of the 24 samples, only 12.5% to 25% of the 
purified DNA samples had the desired sequences. This 
may due to the high error rate of recombinant Taq DNA 
polymerase. 
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Table 2. Comparison of percentage homology between mouse and human framework regions (a) 
and percentage of mismatched mouse-human residues on VH (b) and VL (c) of anti-C2 monoclonal 
antibody obtained using IgBLAST. The mismatched mouse-human residues were humanized with 
the corresponding residues that are present in at least 90% of all the human residues analyzed (*). 
 
(a) Frameworks 
Homology (%) 
VH VL 
1 75.9 82.0 
2 71.0 80.0 
3 67.7 87.8 
   
(b) Framework 3-VL 
Mismatched residue Mouse Human (%) 
*68 T S (100.0) 
   
*81 R 
S (90.3) 
G (5.8) 
C (1.9) 
R (1.0) 
N (1.0) 
   
88 L 
F (64.1) 
V (24.3) 
E (5.8) 
A (2.9) 
I (1.9) 
T (1.0) 
   
 (c) Framework 1-VH 
Mismatched residue Mouse Human (%) 
*10 D 
G (91.2) 
T (6.8) 
V (1.0) 
I (1.0) 
   
16 Q 
E (44.7) 
Q (29.1) 
R (14.6) 
D (6.8) 
G (4.8) 
   
17 S 
T (85.4) 
S (14.6) 
 
25 T 
S (86.4) 
Y (12.6) 
T (1.0) 
 
 
 
Characterization of mAbs 
 
SDS-PAGE  
 
From the SDS-PAGE analysis, bands of approximately 
150 kDa were stained for all mAbs under non-reducing 
conditions (Figure 2a). Under reducing conditions (Figure 
2b), two bands of approximately 55 and 25 kDa, 
corresponding to VH and VL, respectively, were identified 
for all mAbs. No  other  additional  bands  were   detected 
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Figure 1. Agarose gel electrophoresis profiles of humanization of residue 10 of mouse VH (a and b) and 68 of VL (c 
and d). PCR-1 and PCR-2 are mutagenesis-PCR which introduces the specific amino acid humanization. PCR-3 is 
an overlapping-PCR which overlaps both PCR-1 and PCR-2 products. The products of PCR-1 and PCR-2 of VH (a) 
were approximately 150 and 350 bp, respectively, while that for VL (c) were approximately 300 and 100 bp, 
respectively. The products of PCR-3 of VH (b) and VL (d) were 500 and 400 bp, respectively. 100 bp DNA ladder 
(M) was used as reference.  
 
 
 
under both non-reducing and reducing conditions, 
indicating that all the purified mAbs were not 
contaminated with significant quantities of endogenous 
orexogenous proteins. Since mAbs were produced in 
serum-free environment, all the purified mAbs were free 
from bovine polyclonal IgG antibody contamination. 
 
 
In vitro binding studies 
 
Immunofluorescence assay: A critical issue concerning 
humanized antibodies is the possible loss of binding 
ability after modifications are made to reduce their 
immunogenicity. Therefore, the functionality of the 
humanized antibodies is usually evaluated using 
conventional ELISA which requires antigens in purified 
form. Given the lack of commercially-available purified 
form of C2 antigen, a cell-based ELISA was used instead 
(Vazquez et al., 1995; Solano et al., 2003; Ramos-
Suzarte et al., 2007). This assay uses SW1116 cell which 
is a colorectal adenocarcinoma cell-line expressing C2 
antigen on its surface as the capture antigen in what is 
otherwise a conventional antigen-based ELISA. Since 
SW1116 cells are adherent cells, live SW1116 cells were 
used initially to avoid potential alteration of the epitope on 
the C2 antigen caused by drying or fixation (Hong et al., 
2004). Although cell-binding was observed, the variation 
in   binding   of   the   triplicate  wells  with  live  cells  was 
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(a)            (b)   
 
Figure 2. In vitro characterization of purified mAbs using SDS-PAGE under non-reducing (a) and reducing 
conditions (b). From the SDS-PAGE analysis, bands of approximately 150 kDa were stained for all mAbs under 
non-reducing conditions. Under reducing conditions, two bands of approximately 55 and 25 kDa, corresponding 
to the VH and VL, were identified for all mAbs. No additional bands were detected under both conditions. 
 
 
 
significantly higher compared to the situation where fixed 
SW1116 cells were used. Microscopic examination 
revealed that significant loss of non-fixed live SW1116 
cells occurred during washing. In contrast, the use of 
fixation solution might have anchored cells firmly in the 
wells, but still preserved the structure of C2 antigen and 
therefore decreased the experimental variation for 
consistent and reproducible cell-binding ELISA results 
(Yang et al., 2003).  
From the cell-based IFA with H1C2, H2C2, QC2 and 
MC2 mAbs (Figure 3), high fluorescence images were 
obtained compared to wells where unspecific human and 
mouse antibodies were used. Intense fluorescence was 
seen in wells incubated with H1C1 and H2C2 mAbs, as 
with QC2 and MC2 mAbs. This shows that both H1C2 
and H2C2 mAbs were still able to bind to C2 antigen 
expressed on SW1116 cells. This is to be expected 
because no humanization was done on mouse residues 
in the CDR or Vernier zone which are both important for 
antigen recognition (Mateo et al., 2000). 
 
Competitive cell-based ELISA: Figure 4 compares the 
immunoreactivity of H1C2, H2C2 and QC2 mAbs to C2 
antigen expressed on SW1116 colorectal carcinoma. 
Competitive ELISA showed that MC2 mAb was inhibited 
in a dose-dependent manner by increasing 
concentrations of chimeric and humanized anti-C2 mAbs. 
Half displacement concentrations of H1C2, H2C2 and 
QC2 mAbs were 1.6, 1.7 and 0.85 g/ml, respectively, 
(Figure 4). Thus, the mutations introduced in the variable 
region of humanized anti-C2 mAbs provoked 
approximately 50% reduction in binding affinity for both 
H1C2 and H2C2 mAbs. 
 
 
In vivo immunogenicity studies 
 
The next critical issue was whether the humanized mAbs 
developed by logical approach method would have a 
decreased immunogenicity when they  were administered 
 in humans. To address this issue, M. fascicularis were 
used because of the similarity of monkeys’ immune 
system to that of humans’, thus providing a reliable 
indicator of potential human AAR. Although M. 
fascicularis are only listed in appendix II (currently not 
threatened with extinction) by Convention on International 
Trade in Endangered Species of Wild Fauna and Flora 
(CITES), in Malaysia, however, it is classified as a 
protected animal, under schedule two of the Protection of 
Wild Life Act 76, 1972. Due to the stringent laws and 
regulations in Malaysia, only five captive-born M. 
fascicularis were permitted to be used for this study. For 
immunization, the intradermal route was chosen because 
of the high population of matured dendritic cells in the 
dermis layer of the skin (Cui et al., 2003). During the 
study, no evident changes in behavior, food consumption 
and body mass were observed in all M. fascicularis. 
Compared to M. fascicularis immunized with humanized 
and chimeric anti-C2 mAbs, the M. fascicularis 
immunized with MC2 mAb had the highest monkey IgG 
and IgM AAR irrespective whether MC2 mAb (Figure 5) 
or QC2 mAb (Figure 6) was used as capture antibody. 
Decreased but significant AAR responses were obtained 
when M. fascicularis were immunized with QC2 and 
H2C2 mAbs. However, it can be seen that when H1C2 
mAb was used as immunogen, the monkey’s AAR was 
similar to that of those immunized with placebo (Figures 5 
and 6). 
 
 
DISCUSSION 
 
In general, H2C2 mAb was still able to bind to C2 antigen 
expressed on SW1116 cells, which shows that the 
humanized mAb developed using logical approach 
method was still functional. In terms of affinity, a 
reduction of ~50% was observed for H2C2 mAb (logical 
approach method) and also in H1C2 mAb 
(deimmunization method). Nevertheless, while both 
H1C2   and   H2C2  mAbs  had  reduced  immunogenicity
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d) e) f) 
   
 
 
 
Figure 3. In vitro characterization of purified mAbs by cell-based IFA using colorectal carcinoma expressing C2 antigen. From 
the cell-based studies, cell-binding were observed as indicated by the high fluorescence in images obtained when H1C2 (a), 
H2C2 (b), QC2 (c) and MC2 (d) mAbs were used, compared to the lack of fluorescence in images using unspecific human (e) 
and mouse (f) control antibodies. This demonstrates that even after humanization both H1C2 and H2C2 mAbs developed 
using deimmunization and logical approach methods, respectively, were still functional.  
 
 
 
compared to MC2 mAb, however only H1C2 mAb had its 
immunogenicity virtually eliminated. On the other hand, 
the immunogenicity of H2C2 mAb was still similar to that 
of QC2 mAb. The reduced immunogenicity of H1C2 mAb 
compared to H2C2 mAb may be due to the fact that 
H1C2 mAb have less amphipathic regions compared to 
that of H2C2 mAb. In VH of H1C2 mAb, the humanized 
residues 10 and 17 are located in the first amphipathic 
region, whereas the remaining humanized residues 44 
and 45 are located in the second amphipathic region 
(Roque-Navarro et al., 2003). Similarly, in VL of H1C2 
mAb, the humanized residue 15 is located in the first 
amphipathic region and residue 50 is located in the 
second amphipathic region. Therefore, both chains of 
H1C2 mAb had only 1 remaining amphipathic region; VH 
(third amphipathic region) and VL (third amphipathic 
region).  
On the other hand, the H2C2 mAb developed using 
logical approach method had one humanized residue 10 
in VH which is in the first amphipathic region and 2 
humanized residues 68 and 81 which are in the second 
amphipathic region in VL. Thus, H2C2 mAb have two 
remaining amphipathic regions in each VH (second and 
third amphipathic regions) and in VL (first and third 
amphipathic regions). The additional amphipathic regions 
may have caused the immunogenicity of H2C2 mAb to be 
higher that of H1C2 mAb. The deimmunization method 
combines veneering (based on Padlan’s approach) 
(Mateo et al., 1997) to effectively humanize surface 
residues (thus removing B-cell epitopes) with the 
identification and removal of potential helper T-cell 
epitopes from engineered antibodies. Helper T-cell 
epitopes are short peptide sequences within proteins that 
bind   to   MHC   class   II   molecules.  The  peptide-MHC 
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Figure 4. In vitro reactivity of purified antibody reactivity measured by competitive cell-based ELISA. 
Displacement of MC2 mAb binding to C2 antigen, a membrane glycoprotein expressed in SW1116 human 
colorectal cell line-coated plates, by H1C2 (blue line), H2C2 (red line), and QC2 (green line) mAbs. An 
unspecific human mAb (purple line) was included as negative control. 
 
 
 
class II complexes are recognized by T-cells, and trigger 
the activation and differentiation of helper T-cells, thus 
stimulating a cellular immune response. Helper T-cells 
initiate and maintain immunogenicity by interacting with 
B-cells, resulting in the production of antibodies that bind 
specifically to the administered antibody. In 
deimmunization method, helper T-cell epitopes are 
identified within the primary sequence of the antibody 
using prediction software and these sequences are 
altered by amino acid substitution to avoid recognition by 
T-cells. Thus, the nature of the protein surface is 
important for its recognition by the monkey or human 
immune system because the protein internalization and 
processing by antigen-presenting cells and the 
presentation of processed peptides to T-helper cells in 
the context of class II major histocompatibilty complex 
molecules are also essential events for the development 
of an immune response against administered mAbs 
(Mateo et al., 2000). Therefore, the removal of most 
linear epitopes that may have been presented to T-cells 
had considerably reduced the immunogenicity of H1C2 
mAb. In contrast, the presence of additional potential T-
cell epitopes of H2C2 mAb even after humanization may 
have contributed to its higher immunogenicity. 
Hence the deimmunization method is a superior 
method for the development of functional humanized 
mAbs with reduced immunogenicity. The fact that, 
deimmunization method had also been applied previously 
on ior-egf/r3, a mouse mAb which blocks the epidermal 
growth factor receptor (EFGR) and the resulting 
humanized antibody retained its antigen-binding affinity 
and was less immunogenic in monkeys than either their 
mouse or chimeric predecessors, further proves the 
superiority of deimmunization method compared to 
logical approach method (Mateo et al., 2000).  
 
 
Conclusion 
 
In conclusion, although the small number of monkeys 
permitted for this study prelude statistical analysis of the 
data, it is noteworthy that M. fascicularis immunized with 
humanized anti-C2 (H2C2) mAb had reduced 
immunogenicity compared to  M.  fascicularis  immunized
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Figure 5. Monkeys’ anti-antibody responses to mouse-, chimeric- and humanized anti-C2 antibodies using 
MC2 mAb as capture antibody. These graphs show the AAR of monkeys to MC2 (red), QC2 (blue), H1C2 
(purple), and H2C2 (green) mAbs as measured by titers of IgM (a) and IgG (b). MC2 mAbs were used as 
capture antibody. For negative control, M. fascicularis was immunized with placebo (black). 
 
 
 
with mouse anti-C2 mAb. While both humanized anti-C2 
mAbs; H1C2 and H2C2 mAbs developed by 
deimmunization and logical approach method, 
respectively, are functional and have 50% reduction in 
binding affinity, the reduced immunogenicity using logical 
approach method however is not guaranteed as indicated 
by H2C2 mAb. Therefore, for the development of 
functional humanized mAbs with reduced AAR, it is 
recommended that amphipathic mouse residues be 
targeted for humanization, while those located in the 
CDR or Vernier zone be left alone. Therefore, it is 
concluded that the deimmunization method should be 
used to humanize mouse monoclonal antibodies. The 
retention of functionality and induction of minimal AAR 
make humanized H1C2 mAbs ideal for use in human 
therapeutics. 
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Figure 6. Monkeys’ anti-antibody responses to mouse-, chimeric- and humanized anti-C2 antibodies using 
QC2 mAb as capture antibody. These graphs show the AAR of monkeys to MC2 (red), QC2 (blue), H1C2 
(purple), and H2C2 (green) mAbs as measured by titers of IgM (a) and IgG (b). QC2 mAbs were used as 
capture antibody. For negative control, M. fascicularis was immunized with placebo (black). 
 
 
 
Abbreviations: AAR, Anti-antibody response; CDR, 
complementary determining regions; H1C2, humanized 
anti-C2 mAb developed using deimmunization method; 
H2C2, humanized anti-C2 mAb developed using logical 
approach method; IFA, immunofluorescence assay; M. 
fascicularis, Macacca fascicularis; mAb, monoclonal 
antibody; MC2, mouse anti-C2 mAb; QC2, chimeric anti- ] 
C2 mAb; VH, variable region of the heavy chain; VL, 
variable region of the light chain. 
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